Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al
- PMID: 31964656
- DOI: 10.1136/annrheumdis-2019-216598
Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al
Keywords: autoimmune diseases; inflammation; rheumatoid arthritis.
Conflict of interest statement
Competing interests: MR, RL, and DK are inventors for patent applications related to the therapeutic use of ld-IL2, which belongs to their academic institutions and has been licensed to ILTOO Pharma. MR and DKhold shares in ILTOO Pharma. No other potential conflicts of interest relevant to this article were reported
Comment on
-
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472651 Clinical Trial.
-
Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.Ann Rheum Dis. 2021 Dec;80(12):e196. doi: 10.1136/annrheumdis-2019-216576. Epub 2019 Nov 19. Ann Rheum Dis. 2021. PMID: 31744827 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
